Innoviva (INVA) Non-Current Deffered Revenue (2010 - 2017)
Innoviva posted quarterly Non-Current Deffered Revenue of $1.6 million for Q3 2017, down 36.3% year-on-year from $2.4 million in Q3 2016, and down 12.47% on a QoQ basis from $1.8 million in Q2 2017.
Innoviva (INVA) has 8 years of Non-Current Deffered Revenue data on file, last reported at $1.6 million in Q3 2017.
- For the quarter ending Q3 2017, Non-Current Deffered Revenue fell 36.3% year-over-year to $1.6 million; the trailing twelve-month figure through Sep 2017 stood at $1.6 million (down 36.3% YoY), and the FY2016 full-year result was $2.2 million, down 28.56% from the prior year.
- Non-Current Deffered Revenue for Q3 2017 stood at $1.6 million, down from $1.8 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $5.7 million in Q1 2013 and bottomed at $100000.0 in Q3 2015.
- The 5-year median for Non-Current Deffered Revenue is $3.1 million (2015), against an average of $3.2 million.
- The widest annual swing landed in 2015, when Non-Current Deffered Revenue plunged 97.64%; it then jumped 2503.92% in 2016.
- A 5-year view of Non-Current Deffered Revenue shows it stood at $5.5 million in 2013, then plunged by 30.56% to $3.8 million in 2014, then dropped by 18.19% to $3.1 million in 2015, then slipped by 28.56% to $2.2 million in 2016, then fell by 29.95% to $1.6 million in 2017.
- The last three Non-Current Deffered Revenue figures came in at $1.6 million (Q3 2017), $1.8 million (Q2 2017), and $2.0 million (Q1 2017), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 225.10 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2017 | 1.55 Mn |
| Jun 30, 2017 | 1.77 Mn |
| Mar 31, 2017 | 1.99 Mn |
| Dec 31, 2016 | 2.21 Mn |
| Sep 30, 2016 | 2.44 Mn |
| Jun 30, 2016 | 2.66 Mn |
| Mar 31, 2016 | 2.88 Mn |
| Dec 31, 2015 | 3.10 Mn |
| Sep 30, 2015 | 100,000.00 |
| Jun 30, 2015 | 102,000.00 |
| Mar 31, 2015 | 3.76 Mn |
| Dec 31, 2014 | 3.79 Mn |
| Sep 30, 2014 | 4.06 Mn |
| Jun 30, 2014 | 4.33 Mn |
| Mar 31, 2014 | 4.89 Mn |
| Dec 31, 2013 | 5.46 Mn |
| Sep 30, 2013 | 4.66 Mn |
| Jun 30, 2013 | 4.70 Mn |
| Mar 31, 2013 | 5.67 Mn |
| Dec 31, 2012 | 6.01 Mn |
| Sep 30, 2012 | 5.79 Mn |
| Jun 30, 2012 | 5.48 Mn |
| Mar 31, 2012 | 7.84 Mn |
| Dec 31, 2011 | 122.02 Mn |
| Sep 30, 2011 | 124.44 Mn |
| Jun 30, 2011 | 127.39 Mn |
| Dec 31, 2010 | 137.43 Mn |